Avacta Group PLC (LON:AVCT)
79.00p+3.95%
Spriggl Score: Weak— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Cancer drug trial approved by regulators; urgently needs a pharma partner before cash runs out.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer dru…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £339.7M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Avacta Group PLC and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free